GenMark is a provider of automated, multiplex molecular-dx testing systems that detect and measure DNA and RNA targets to diagnose disease and personalize patient treatment. The company currently markets three FDA-cleared IVD tests: the Cystic Fibrosis Genotyping Test, the Warfarin Sensitivity Test, and the Thrombophilia Risk Test.

Commenting on the deal with Advanced Liquid Logic, Hany Massarany, President and CEO of GenMark, said, “This partnership will allow us to leverage both companies’ unique technologies and know-how to deliver a digital sample-to-answer in-vitro diagnostic platform. Our initial focus on multiplex molecular testing will be followed by efforts in other areas of diagnostics including protein detection and point-of-care testing, as we redefine industry standards for performance, reliability, and ease of use with even the most complex of assays.”

Richard West, President and CEO of Advanced Liquid Logic, said, “We are excited to be working with the GenMark team and technology. We bring a unique capability in comprehensive, electronically driven sample preparation and we expect that it will integrate well with GenMark’s eSensor detection technology. This further validates that the fluid-handling flexibility of our platform can be integrated with multiple types of detection for a wide range of applications.”

Advanced Liquid Logic specializes in digital microfluidics: the precise and flexible manipulation of microdroplets using electrical fields. The company provides products in newborn screening and genomics sample preparation.